Frank van Leth

Associate Professor Health Sciences

The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation


Journal article


F. van Leth, F. Brinkmann, D. Cirillo, K. Dheda, R. Duarte, L. Guglielmetti, L. Kukša, C. Lange, C. Mitnick, A. Skrahina, K. Zaman, G. Bothamley
European Respiratory Journal, 2019

Semantic Scholar DOI PubMed
Cite

Cite

APA   Click to copy
van Leth, F., Brinkmann, F., Cirillo, D., Dheda, K., Duarte, R., Guglielmetti, L., … Bothamley, G. (2019). The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation. European Respiratory Journal.


Chicago/Turabian   Click to copy
Leth, F. van, F. Brinkmann, D. Cirillo, K. Dheda, R. Duarte, L. Guglielmetti, L. Kukša, et al. “The Tuberculosis Network European Trials Group (TBnet) ERS Clinical Research Collaboration: Addressing Drug-Resistant Tuberculosis through European Cooperation.” European Respiratory Journal (2019).


MLA   Click to copy
van Leth, F., et al. “The Tuberculosis Network European Trials Group (TBnet) ERS Clinical Research Collaboration: Addressing Drug-Resistant Tuberculosis through European Cooperation.” European Respiratory Journal, 2019.


BibTeX   Click to copy

@article{f2019a,
  title = {The Tuberculosis Network European Trials group (TBnet) ERS Clinical Research Collaboration: addressing drug-resistant tuberculosis through European cooperation},
  year = {2019},
  journal = {European Respiratory Journal},
  author = {van Leth, F. and Brinkmann, F. and Cirillo, D. and Dheda, K. and Duarte, R. and Guglielmetti, L. and Kukša, L. and Lange, C. and Mitnick, C. and Skrahina, A. and Zaman, K. and Bothamley, G.}
}

Abstract

While the incidence of tuberculosis (TB) has fallen steadily within the European Union, the region has by far the highest estimated incidence of multidrug-resistant (MDR)-TB among TB patients [1, 2], which hampers the goal of the World Health Organization (WHO) of TB elimination in the region [3]. MDR-TB has the potential to be the most important infectious threat to European health over the coming decades, unless effective treatment can be found and relapses prevented. The Tuberculosis Network European Trials group (TBnet) continues the successful ERS Clinical Research Collaboration on drug-resistant tuberculosis http://ow.ly/gGH330mHrDa